Medrx Co.,Ltd. Logo

Medrx Co.,Ltd.

Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.

4586 | T

Overview

Corporate Details

ISIN(s):
JP3921220004
LEI:
Country:
Japan
Address:
東かがわ市西山431番地7
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Medrx Co., Ltd., established in 2002, is a pharmaceutical company focused on drug formulation development. The company specializes in creating new dosage forms and value-added medicines, with a core technological expertise in transdermal absorption and drug delivery systems. Medrx conducts research and development to create innovative pharmaceutical candidates, which it then licenses to other companies for final clinical trials, production, and commercialization. The company's primary goal is to improve global health and patient quality of life by developing medications that offer alternatives to conventional oral administration, thereby improving patient adherence and therapeutic effectiveness.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 08:33
Interim Report
確認書
Japanese 8.9 KB
2025-08-08 08:31
Interim Report
半期報告書-第24期(2025/01/01-2025/12/31)
Japanese 425.8 KB
2025-06-13 08:31
Share Issue/Capital Change
臨時報告書
Japanese 39.1 KB
2025-03-31 08:33
Governance Information
内部統制報告書-第23期(2024/01/01-2024/12/31)
Japanese 23.9 KB
2025-03-31 08:32
Registration Form
確認書
Japanese 8.7 KB
2025-03-31 08:32
Post-Annual General Meeting Information
臨時報告書
Japanese 25.0 KB
2025-03-31 08:32
Registration Form
訂正有価証券届出書(組込方式)
Japanese 271.6 KB
2025-03-31 08:31
Registration Form
有価証券報告書-第23期(2024/01/01-2024/12/31)
Japanese 1.4 MB
2025-03-28 07:31
Registration Form
訂正有価証券届出書(組込方式)
Japanese 268.0 KB
2025-03-25 07:31
Registration Form
有価証券届出書(組込方式)
Japanese 409.6 KB
2024-08-09 08:01
Interim Report
確認書
Japanese 8.8 KB
2024-08-09 08:00
Interim Report
半期報告書-第23期(2024/01/01-2024/12/31)
Japanese 345.0 KB
2024-05-17 08:01
Share Issue/Capital Change
臨時報告書
Japanese 39.2 KB
2024-05-10 08:02
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-10 08:01
Quarterly Report
四半期報告書-第23期第1四半期(2024/01/01-2024/03/31)
Japanese 408.3 KB

Automate Your Workflow. Get a real-time feed of all Medrx Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Medrx Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Medrx Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.